BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors
BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors
NEW YORK, Dec. 17, 2020 BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Jeffrey Vacirca to its Board of Directors to help guide the company as it seeks commercial approval following announcement of positive Phase 3 data from the PROTECTIVE-2 study of plinabulin in combination with pegfilgrastim for protection against chemotherapy-induced neutropenia.
“We are delighted to welcome Dr. Vacirca as a member of our Board of Directors, especially given his impressive leadership within the oncology community,” said Dr. Lan Huang, Founder and Chief Executive Officer of BeyondSpring. “In addition to his many years as an accomplished oncology clinician, D
Is SCHN A Good Stock To Buy Now? yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
email article
An oral taxane plus reduced-dose capecitabine increased the progression-free interval in metastatic breast cancer (MBC) by about 3 months, initial results from a randomized trial showed.
Patients treated with tesetaxel and capecitabine had a median progression-free survival of 9.8 months as compared with 6.9 months with capecitabine monotherapy. Two-thirds of patients in the tesetaxel arm had disease control at 24 weeks versus half of those in the placebo group, and the all-oral combination regimen led to significantly more objective responses.
The benefits were consistent across prespecified subgroups and occurred within the context of a manageable side-effect profile, Joyce O Shaughnessy, MD, of Baylor University Medical Center in Dallas, reported during the San Antonio Breast Cancer Symposium virtual meeting.